Cargando…
PBK drives PARP inhibitor resistance through the TRIM37/NFκB axis in ovarian cancer
Resistance to PARP inhibitors (PARPi) remains a therapeutic challenge in ovarian cancer patients. PDZ-binding kinase (PBK) participates in the chemoresistance of many malignancies. However, the role of PBK in PARPi resistance of ovarian cancer is obscure. In the current study, we demonstrated that o...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355941/ https://www.ncbi.nlm.nih.gov/pubmed/35859118 http://dx.doi.org/10.1038/s12276-022-00809-w |